Take Home Points on Non-Inferiority Studies
- Non-inferiority studies should be done when a new treatment (or diagnostic modality) requires less resources (cost or time), is easier for the patient or has a lower side-effect profile.
- Non-inferiority study design largely negates the protections against bias added by blinding and randomization.
- Non-inferiority studies can be used to manipulate clinicians when a superiority study would be more appropriate.
REBEL Core Cast 8.0 – The NEJM + Non-Inferiority Studies
- REBEL EM: Omadacycline, the NEJM and Non-Inferiority Studies
- First 10 EM: Andexanet Alfa: More Garbage Science in the New England Journal of Medicine
- EM Nerd: The Case of the Scientific Ruse
- Stets R et al. Omadacycline for Community-Acquired Bacterial Pneumonia. NEJM 2019; 380(6): 511-27. PMID: 30726692
- O’Riordan W et al. Omadacycline for Acute Bacterial Skin and Skin-Structure Infections. NEJM 2019; 380(6): 528-38. PMID: 30726689
- Lundh A et al. Industry sponsorship and research outcome: systematic review with meta-analysis. Intensive Care Med 2018; 44(10): 1603-12. PMID: 30132025
Show Notes Written By: Miguel Reyes, MD (Twitter: @Miguel_ReyesMD)
Post Peer Reviewed By: Salim R. Rezaie, MD (Twitter: @srrezaie)
Latest posts by Anand Swaminathan (see all)
- REBEL Core Cast 67.0 – Tips for Medical Education - October 27, 2021
- REBEL Core Cast 66.0 – Congenital Cardiac Issues - October 13, 2021
- REBEL Cast Ep101: The TOMAHAWK Trial – Angiography after OHCA without STEMI - October 11, 2021